Cargando…
SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test
The SARS-CoV-2 neutralizing antibodies response is the best indicator of effective protection after infection and/or vaccination, but its evaluation requires tedious cell-based experiments using an infectious virus. We analyzed, in 105 patients with various histories of SARS-CoV-2 infection and/or v...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782962/ https://www.ncbi.nlm.nih.gov/pubmed/36556429 http://dx.doi.org/10.3390/life12122064 |
_version_ | 1784857464274944000 |
---|---|
author | Marot, Stephane Bocar Fofana, Djeneba Flandre, Philippe Malet, Isabelle Zafilaza, Karen Leducq, Valentin Vivien, Diane Mrabet, Sarah Poignon, Corentin Calvez, Vincent Morand-Joubert, Laurence Marcelin, Anne-Geneviève Gozlan, Joel |
author_facet | Marot, Stephane Bocar Fofana, Djeneba Flandre, Philippe Malet, Isabelle Zafilaza, Karen Leducq, Valentin Vivien, Diane Mrabet, Sarah Poignon, Corentin Calvez, Vincent Morand-Joubert, Laurence Marcelin, Anne-Geneviève Gozlan, Joel |
author_sort | Marot, Stephane |
collection | PubMed |
description | The SARS-CoV-2 neutralizing antibodies response is the best indicator of effective protection after infection and/or vaccination, but its evaluation requires tedious cell-based experiments using an infectious virus. We analyzed, in 105 patients with various histories of SARS-CoV-2 infection and/or vaccination, the neutralizing response using a virus neutralization test (VNT) against B.1, Alpha, Beta and Omicron variants, and compared the results with two surrogate assays based on antibody-mediated blockage of the ACE2-RBD interaction (Lateral Flow Boditech and ELISA Genscript). The strongest response was observed for recovered COVID-19 patients receiving one vaccine dose. Naïve patients receiving 2 doses of mRNA vaccine also demonstrate high neutralization titers against B.1, Alpha and Beta variants, but only 34.3% displayed a neutralization activity against the Omicron variant. On the other hand, non-infected patients with half vaccination schedules displayed a weak and inconstant activity against all isolates. Non-vaccinated COVID-19 patients kept a neutralizing activity against B.1 and Alpha up to 12 months after recovery but a decreased activity against Beta and Omicron. Both surrogate assays displayed a good correlation with the VNT. However, an adaptation of the cut-off positivity was necessary, especially for the most resistant Beta and Omicron variants. We validated two simple and reliable surrogate neutralization assays, which may favorably replace cell-based methods, allowing functional analysis on a larger scale. |
format | Online Article Text |
id | pubmed-9782962 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97829622022-12-24 SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test Marot, Stephane Bocar Fofana, Djeneba Flandre, Philippe Malet, Isabelle Zafilaza, Karen Leducq, Valentin Vivien, Diane Mrabet, Sarah Poignon, Corentin Calvez, Vincent Morand-Joubert, Laurence Marcelin, Anne-Geneviève Gozlan, Joel Life (Basel) Article The SARS-CoV-2 neutralizing antibodies response is the best indicator of effective protection after infection and/or vaccination, but its evaluation requires tedious cell-based experiments using an infectious virus. We analyzed, in 105 patients with various histories of SARS-CoV-2 infection and/or vaccination, the neutralizing response using a virus neutralization test (VNT) against B.1, Alpha, Beta and Omicron variants, and compared the results with two surrogate assays based on antibody-mediated blockage of the ACE2-RBD interaction (Lateral Flow Boditech and ELISA Genscript). The strongest response was observed for recovered COVID-19 patients receiving one vaccine dose. Naïve patients receiving 2 doses of mRNA vaccine also demonstrate high neutralization titers against B.1, Alpha and Beta variants, but only 34.3% displayed a neutralization activity against the Omicron variant. On the other hand, non-infected patients with half vaccination schedules displayed a weak and inconstant activity against all isolates. Non-vaccinated COVID-19 patients kept a neutralizing activity against B.1 and Alpha up to 12 months after recovery but a decreased activity against Beta and Omicron. Both surrogate assays displayed a good correlation with the VNT. However, an adaptation of the cut-off positivity was necessary, especially for the most resistant Beta and Omicron variants. We validated two simple and reliable surrogate neutralization assays, which may favorably replace cell-based methods, allowing functional analysis on a larger scale. MDPI 2022-12-09 /pmc/articles/PMC9782962/ /pubmed/36556429 http://dx.doi.org/10.3390/life12122064 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Marot, Stephane Bocar Fofana, Djeneba Flandre, Philippe Malet, Isabelle Zafilaza, Karen Leducq, Valentin Vivien, Diane Mrabet, Sarah Poignon, Corentin Calvez, Vincent Morand-Joubert, Laurence Marcelin, Anne-Geneviève Gozlan, Joel SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test |
title | SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test |
title_full | SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test |
title_fullStr | SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test |
title_full_unstemmed | SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test |
title_short | SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test |
title_sort | sars-cov-2 neutralizing responses in various populations, at the time of sars-cov-2 variant virus emergence: evaluation of two surrogate neutralization assays in front of whole virus neutralization test |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782962/ https://www.ncbi.nlm.nih.gov/pubmed/36556429 http://dx.doi.org/10.3390/life12122064 |
work_keys_str_mv | AT marotstephane sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest AT bocarfofanadjeneba sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest AT flandrephilippe sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest AT maletisabelle sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest AT zafilazakaren sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest AT leducqvalentin sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest AT viviendiane sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest AT mrabetsarah sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest AT poignoncorentin sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest AT calvezvincent sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest AT morandjoubertlaurence sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest AT marcelinannegenevieve sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest AT gozlanjoel sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest |